P
Patrick L. McGeer
Researcher at University of British Columbia
Publications - 569
Citations - 61292
Patrick L. McGeer is an academic researcher from University of British Columbia. The author has contributed to research in topics: Microglia & Alzheimer's disease. The author has an hindex of 122, co-authored 569 publications receiving 58584 citations. Previous affiliations of Patrick L. McGeer include Laval University & Kyoto University.
Papers
More filters
Journal ArticleDOI
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain.
TL;DR: Data establish that the association of Ckidelta with the tau pathology of AD is reflective of an increase in gene transcription, and shows that the CKidelta isoform may play an important role in this fundamental aspect of AD pathology.
Journal Article
Positron emission tomography in patients with clinically diagnosed Alzheimer's disease
Patrick L. McGeer,H. Kamo,R. Harrop,David K.B. Li,H. Tuokko,Edith G. McGeer,Michael J. Adam,W Ammann,B. L. Beattie,D B Calne +9 more
TL;DR: A detailed analysis of LCMR-gl values in selected cerebral regions of various sizes refuted the hypothesis that the reduction in cortical glucose metabolism in Alzheimer's disease is due to the filling by metabolically inert cerebrospinal fluid of space created by tissue atrophy.
Journal ArticleDOI
Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease
TL;DR: Immunopositivity was detected in association with lamellated bodies in the neuronal cytoplasm, lipofuscin granules, lysosomes and neurofibrillary tangles, providing further evidence that complement-mediated injury of neurons plays a part in the pathophysiology of AD.
Journal ArticleDOI
Positron tomography and nuclear magnetic resonance imaging.
TL;DR: New developments in emission tomography, nuclear magnetic resonance imaging, and in vivo spectroscopy offer new horizons for medical research and clinical activities.
Journal ArticleDOI
Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation: POTENTIAL FOR TREATING PARKINSON DISEASE*
Moonhee Lee,Valerio Tazzari,Daniela Giustarini,Ranieri Rossi,Anna Sparatore,Piero Del Soldato,Edith G. McGeer,Patrick L. McGeer +7 more
TL;DR: Four l-DOPA hybrid compounds based on coupling l- DOPA to four different hydrogen sulfide-donating compounds may be useful for the treatment of PD because of their significant antiinflammatory, antioxidant, and neuroprotective properties.